Skip to main content
SpringerLink
Log in

Kommentar zu „ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation – executive summary“

“ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation – executive summary” – comments by the German Cardiac Society

  • Leitlinien
  • Published:
Der Kardiologe Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4
Abb. 5

Literatur

  1. Wyse DG, Waldo AL DiMarco JP et al. (2002) A comparison of rate control and rhythm control in patients with atrial.N Engl J Med 347: 1825–1833 (AFFIRM)

    PubMed  CAS  Google Scholar 

  2. Van Gelder IC, Hagesn VE, Bosker HA et al. (2002) A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 347: 1834–1840 (RACE)

    Article  Google Scholar 

  3. Hohnloser SH, Kuck KH, Lilienthal J (2000) Rhythm or rate control in atrial fibrillation – pharmacological intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet 356: 1789–1794

    Article  PubMed  CAS  Google Scholar 

  4. Carlsson J, Miketic S, Windeler J et al. (2003) Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol 41: 1690–1696

    Article  PubMed  Google Scholar 

  5. Opolski G, Torbicki A, Kosior DA et al. (2004) Rate control vs. rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study. Chest 126: 476–486

    Article  PubMed  Google Scholar 

  6. Grönefeld GC, Lilienthal J, Kuck KH et al. (2003) Impact of rate versus rhythm control on quality of life in patients with persistent atrial fibrillation. Results from a prospective randomized study. Eur Heart J 24: 1430–1436

    Article  PubMed  Google Scholar 

  7. Hagens VE, Ranchor AV, Van SE et al. (2004) Effect of rate or rhythm control on quality of life in persistent atrial fibrillation. Results from the Rate Control Versus Electrical Cardioversion (RACE) Study. J Am Coll Cardiol 43: 241–247

    Article  PubMed  Google Scholar 

  8. Nerheim P, Birger-Botkin S, Piracha L et al. (2004) Heart failure and sudden death in patients with tachycardia-induced cardiomyopathy and recurrent tachycardia. Circulation 110: 247–252

    Article  PubMed  Google Scholar 

  9. AFFIRM Investigators (2004) Relationship between sinus rhythm, treatment, and survival in the atrial fibrillation follow-up investigation of rhythm management (AFFIRM) Study. Circulation 109: 1509–1513

    Article  Google Scholar 

  10. Prystowsky EN, Benson DW Jr, Fuster V et al. (1996) Management of patients with atrial fibrillation. A statement for healthcare professionals. From the Subcommittee on Electrocardiography and Eletrophysiology, American Heart Association. Circulation 93: 1262–1277

    PubMed  CAS  Google Scholar 

  11. Brignole M, Menozzi C, Gianfranchi L et al. (1998) Assessment of atrioventricular junction ablation and VVIR pacemaker versus pharmacological treatment in patients with heart failure and chronic atrial fibrillation: a randomized, controlled study. Circulation 98: 953–960

    PubMed  CAS  Google Scholar 

  12. Kay GN, Ellenbogen KA, Giudici M et al. (1998) The Ablate and Pace Trial: a prospective study of catheter ablation of the AV conduction system and permanent pacemaker implantation for treatment of atrial fibrillation. APT Investigators. J Interv Card Electrophysiol 2: 121–135

    Article  PubMed  CAS  Google Scholar 

  13. Brignole M, Gianfranchi L, Menozzi C et al. (1997) Assessment of atrioventricular junction ablation and DDDR mode-switching pacemaker versus pharmacological treatment in patients with severely symptomatic paroxysmal atrial fibrillation: a randomized controlled study. Circulation 96: 2617–2624

    PubMed  CAS  Google Scholar 

  14. Wood MA, Brown-Mahoney C, Kay GN et al. (2000) Clinical outcomes after ablation and pacing therapy for atrial fibrillation: a meta-analysis. Circulation 101: 1138–1144

    PubMed  CAS  Google Scholar 

  15. Williamson BD, Man KC, Daoud E et al. (1994) Radiofrequency catheter modification of atrioventricular conduction to control the ventricular rate during atrial fibrillation. N Engl J Med 331: 910–917

    Article  PubMed  CAS  Google Scholar 

  16. Feld GK, Fleck RP, Fujimura O et al. (1994) Control of rapid ventricular response by radiofrequency catheter modification of the atrioventricular node in patients with medically refractory atrial fibrillation. Circulation 90: 2299–2307

    PubMed  CAS  Google Scholar 

  17. Tebbenjohanns J, Schumacher B, Korte T et al. (2000) Bimodal RR interval distribution in chronic atrial fibrillation: impact of dual atrioventricular nodal physiology on long-term rate control after catheter ablation of the posterior atrionodal input. J Cardiovasc Electrophysiol 11: 497–503

    Article  PubMed  CAS  Google Scholar 

  18. Hart RG, Pearce LA, McBride R et al. (1999) Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Stroke 30: 1223–1229

    PubMed  CAS  Google Scholar 

  19. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996;348: 633–638

  20. Gage BF, Waterman AD, Shannon W et al. (2001) Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 285: 2864–2870

    Article  PubMed  CAS  Google Scholar 

  21. van Walraven WC, Hart RG, Wells GA et al. (2003) A clinical prediction rule to identify patients with atrial fibrillation and a low risk for stroke while taking aspirin. Arch Intern Med 163: 936–943

    Article  Google Scholar 

  22. Hart RG, Renavente O, McBride R et al. (1999) Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 131: 492–501

    PubMed  CAS  Google Scholar 

  23. Fang Mc, Chan Y, Hylek EM et al. (2004) Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med 141: 745–252

    PubMed  Google Scholar 

  24. Hart RG, Tonarelli SB, Pearce LA (2005) Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas. Stroke 36: 1588–1593

    Article  PubMed  Google Scholar 

  25. Albers GW, Diener HC, Frison L et al. (2005) Ximelagatran vs. warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 293: 690–698

    Article  PubMed  Google Scholar 

  26. Hylek EM, Skates SJ, Sheehan MA et al. (1996) An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with non-rheumatic atrial fibrillation. N Engl. J Med 335: 540–546

    CAS  Google Scholar 

  27. Connolly S, Pogue J, Hart R et al. (2006) Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 367: 1903–1912

    Article  PubMed  CAS  Google Scholar 

  28. Husted SE, Ziegler BK, Kher A (2006) Long-term anticoagulant therapy in patients with coronary artery disease. Eur Heart J 27: 913–919

    Article  PubMed  CAS  Google Scholar 

  29. Crijns HJ, Van G, I, Walfridsson H et al. (2006) Safe and effective conversion of persistent atrial fibrillation to sinus rhythm by intravenous AZD7009. Heart Rhythm 3: 1321–1331

    Article  PubMed  Google Scholar 

  30. Goldstein RN, Khrestian C, Carlsson L, Waldo AL (2004) Azd7009: a new antiarrhythmic drug with predominant effects on the atria effectively terminates and prevents reinduction of atrial fibrillation and flutter in the sterile pericarditis model. J Cardiovasc Electrophysiol 15: 1444–1450

    Article  PubMed  Google Scholar 

  31. Kirchhof P, Fetsch T, Hanrath P et al. (2005) Targeted pharmacological reversal of electrical remodeling after cardioversion – rationale and design of the Flecainide Short-Long (Flec SL) trial. Am Heart J 150: 899

    Article  PubMed  CAS  Google Scholar 

  32. Alboni P, Tomasi C, Menozzi C et al. (2001) Efficacy and safety of out-of-hospital self-administered single-dose oral drug treatment in the management of infrequent, well-tolerated paroxysmal supraventricular tachycardia. J Am Coll Cardiol 37: 548–553

    Article  PubMed  CAS  Google Scholar 

  33. Alboni P, Botto GL, Baldi N et al. (2004) Outpatient treatment of recent-onset atrial fibrillation with the „pill-in-the-pocket“ approach. N Engl J Med 351: 2384–2391

    Article  PubMed  CAS  Google Scholar 

  34. Fetsch T, Bauer P, Engberding R et al. (2004) Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. Eur Heart J 25: 1385–1394

    Article  PubMed  Google Scholar 

  35. Patten M, Maas R, Bauer P et al. (2004) Suppression of paroxysmal atrial tachyarrhythmias – results of the SOPAT trial. Eur Heart J 25: 1395–1404

    Article  PubMed  Google Scholar 

  36. Patten M, Maas R, Karim A et al. (2006) Event-recorder monitoring in the diagnosis of atrial fibrillation in symptomatic patients: subanalysis of the SOPAT trial. J Cardiovasc Electrophysiol 17: 1216–1220

    Article  PubMed  Google Scholar 

  37. Aksnes TA, Flaa A, Strand A, Kjeldsen SE (2007) Prevention of new-onset atrial fibrillation and its predictors with angiotensin II-receptor blockers in the treatment of hypertension and heart failure. J Hypertens 25: 15–23

    Article  PubMed  CAS  Google Scholar 

  38. Dahlof B, Devereux RB, Kjeldsen SE et al. (2002) Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359: 995–1003

    Article  PubMed  CAS  Google Scholar 

  39. Healey JS, Baranchuk A, Crystal E et al. (2005) Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 45: 1832–1839

    Article  PubMed  CAS  Google Scholar 

  40. Kalus JS, Coleman CI, White CM (2006) The impact of suppressing the renin-angiotensin system on atrial fibrillation. J Clin Pharmacol 46: 21–28

    Article  PubMed  CAS  Google Scholar 

  41. Kizer JR, Dahlof B, Kjeldsen SE et al. (2005) Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study. Hypertension 45: 46–52

    PubMed  CAS  Google Scholar 

  42. Levy S, Ricard P, Gueunoun M et al. (1997) Low-energy cardioversion of spontaneous atrial fibrillation. Immediate and long-term results. Circulation 96: 253–259

    PubMed  CAS  Google Scholar 

  43. Lesser MF (1990) Safety and efficacy of in-office cardioversion for treatment of supraventricular arrhythmias. Am J Cardiol. 1990;66:1267–1268

    Google Scholar 

  44. Joglar JA, Hamdan MH, Ramaswamy K, et al. Initial energy for elective external cardioversion of persistent atrial fibrillation. Am J Cardiol 86: 348–350

  45. Wozakowska-Kaplon B, Janion M, Sielski J et al. (2004) Efficacy of biphasic shock for transthoracic cardioversion of persistent atrial fibrillation: can we predict energy requirements? Pacing Clin Electrophysiol 27: 764–768

    Article  PubMed  Google Scholar 

  46. Oral H, Souza JJ, Michaud GF et al. (1999) Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment. N Engl J Med 340: 1849–1854

    Article  PubMed  CAS  Google Scholar 

  47. Bjerkelund CJ, Orning OM (1969) The efficacy of anticoagulant therapy in preventing embolism related to DC electrical conversion of atrial fibrillation. Am J Cardiol 23: 208–216

    Article  PubMed  CAS  Google Scholar 

  48. Arnold AZ, Mick MJ, Mazurek RP et al. (1992) Role of prophylactic anticoagulation for direct current cardioversion in patients with atrial fibrillation or atrial flutter. J Am Coll Cardiol 19: 851–855

    Article  PubMed  CAS  Google Scholar 

  49. Mancini GB, Goldberger AL (1982) Cardioversion of atrial fibrillation: consideration of embolization, anticoagulation, prophylactic pacemaker, and long-term success. Am Heart J 104: 617–621

    Article  PubMed  CAS  Google Scholar 

  50. Klein AL, Grimm RA, Murray RD et al. (2001) Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med 344: 1411–1420

    Article  PubMed  CAS  Google Scholar 

  51. Moreyra E, Finkelhor RS, Cebul RD (1995) Limitations of transesophageal echocardiography in the risk assessment of nonanticoagulated cardioversion from atrial fibrillation and flutter: an analysis of pooled trials. Am Heart J 129: 71–75

    Article  PubMed  CAS  Google Scholar 

  52. Kirchhof P, Eckardt L, Loh P et al. (2002) Anterior-posterior versus anterior-lateral electrode positions for external cardioversion of atrial fibrillation: a randomized trial. Lancet 360: 1275–1279

    Article  PubMed  Google Scholar 

  53. Glover BM, Walsh SJ, McCann CJ et al. (2007) Biphasic energy selection for transthoracic cardioversion of atrial fibrillation. The BEST AF Trial. Heart June 25 (Epub ahead of print)

  54. Kirchhof P, Mönnig G, Wasmer K et al. (2005) A trial of self-adhesive patch electrodes and hand-held paddle electrodes for external cardioversion of atrial fibrillation (MOBIPAPA). Eur Heart J 26: 1292–1297

    Article  PubMed  Google Scholar 

  55. Madrid A, Bueno MG, Rebollo JMG et al. (2002) Use of Irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation. Circulation 106: 331–336

    Article  PubMed  CAS  Google Scholar 

  56. Suttorp MJ, Kingma JH, Knoomen EM et al. (1999) Recurrence of paroxysmal atrial fibrillation or flutter after successful cardioversion in patients with normal left ventricular function. Am J Cardiol 84: 147R–151R

    Google Scholar 

  57. Van Gelder IC, Crijns H, Tieleman RG et al. (1996) Chronic atrial fibrillation. Success of serial cardioversion therapy and safety of oral anticoagulation. Arch Intern Med 156: 2582–2592

    Google Scholar 

  58. Torp-Pedersen C, Moller M, Bloch-Thompson PE et al. (1999) Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med 341: 857–865

    Article  PubMed  CAS  Google Scholar 

  59. Singh SN, Fletcher RD, Fisher SG et al. (1995) Amiodarone in patients with congestive heart failure and symptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med 333: 77–82

    Article  PubMed  CAS  Google Scholar 

  60. Ehrlich JR, Nattel S, Hohnloser S (2002) Atrial fibrillation and congestive heart failure: specific considerations at the intersection of two common and important cardiac disease sets. J Cardiovasc Electrophysiol 13: 399–405

    Article  PubMed  Google Scholar 

  61. Steeds RP, Birchall AS, Smith M et al. (1999) An open label, randomised, crossover study comparing sotalol and atenolol in the treatment of symptomatic paroxysmal atrial fibrillation. Heart 82: 170–175

    PubMed  CAS  Google Scholar 

  62. Kühlkamp V, Schirdewan A, Stangl K et al. (2000) Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation: a randomised, double-blind, placebo-controlled study. J Am Coll Cardiol 36: 139–146

    Article  PubMed  Google Scholar 

  63. Kober L, Bloch Thomsen PE, Moller M et al. (2002) Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: a randomised trial. Lancet 356: 2052–2058

    Article  Google Scholar 

  64. Peters NS, Schilling RJ, Kanagaratnam P et al. (2002) Atrial fibrillation: strategies to control, combat, and cure. Lancet 359: 593–603

    Article  PubMed  Google Scholar 

  65. Tsang TS, Petty GW, Barnes ME et al. (2003) The prevalence of atrial fibrillation in incident stroke cases and matched population controls in Rochester, Minnesota: changes over three decades. J Am Coll Cardiol 42: 93–100

    Article  PubMed  Google Scholar 

  66. Van Noord T, Tieleman RG, Bosker HA et al. (2004) Beta-blockers prevent subacute recurrences of persistent atrial fibrillation only in patients with hypertension. Europace 6: 343–345

    Article  Google Scholar 

  67. L‘Allier PL, Ducharme A, Keller PF et al. (2004) Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation. J Am Coll Cardiol 44: 159–164

    Article  CAS  Google Scholar 

  68. Schrickel JW, Schwab JO, Yang A et al. (2006) Proarrhythmic effects of amiodarone and concomitant rate-controlling medication. Europace 8: 403–407

    Article  PubMed  Google Scholar 

  69. Cox JL, Schuessler RB, Lappas DG et al. (1996) An 8 1/2-year clinical experience with surgery for atrial fibrillation. Ann Surg 224: 267–273

    Article  PubMed  CAS  Google Scholar 

  70. Cox JL (2004) Cardiac Surgery for arrhythmias. J Cardiovasc Electrophysiol 15: 250–262

    Article  PubMed  Google Scholar 

  71. Cox JL, Boineau JP, Schuessler RB et al. (1995) Modification of the maze procedure for atrial flutter and atrial fibrillation. I. Rationale and surgical results. J ThoracCardiovasc Cirg 110: 473–484

    CAS  Google Scholar 

  72. Damiano RJ Jr, Gaynor SL, Bailey M et al. (2003) The long-term outcome of patients with coronary disease and atrial fibrillation undergoing the Cox maze procedure. J Thorac Cardiovasc Surg 126: 2016–2021

    Article  PubMed  Google Scholar 

  73. Gillinov AM, McCarthy PM (2004) Advances in the surgical treatment of atrial fibrillation. Cardiol Clin 22: 147–155

    Article  PubMed  Google Scholar 

  74. Packer DL, Asirvatham S, Munger TM (2003) Progress in nonpharmacologic therapy of atrial fibrillation. J Cardiovasc Electrophysiol 14: S296–S309

    Article  PubMed  Google Scholar 

  75. Haissaguerre M, Jais P, Shah DC et al. (1998) Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 339: 659–666

    Article  PubMed  CAS  Google Scholar 

  76. Haissaguerre M, Shah DC, Jais P et al. (2000) Electrophysiological breakthroughs from the left atrium to the pulmonary veins. Circulation 102: 2463–2465

    PubMed  CAS  Google Scholar 

  77. Verma A, Marrouche NF, Natale A (2004) Pulmonary vein antrum isolation: intracardiac echocardiography-guided technique. J Cardiovasc Electrophysiol 15: 1335–1340

    Article  PubMed  Google Scholar 

  78. Pappone C, Santinelli V (2004) The who, what, why, and how-to guide for circumferential pulmonary vein ablation. J Cardiovasc Electrophysiol 15: 1226–1230

    Article  PubMed  Google Scholar 

  79. Willems S, Klemm H, Rostock T et al. (2006) Substrate modification combined with pulmonary vein isolation improves outcome of catheter ablation in patients with persistent atrial fibrillation: a prospective randomised comparison. Eur Heart J 27: 2871–2878

    Article  PubMed  Google Scholar 

  80. Wazni OM, Marrouche NF, Martin DO et al. (2005) Radiofrequency ablation vs. antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. JAMA 293: 2634–2640

    Article  PubMed  CAS  Google Scholar 

  81. Oral H, Scharf C, Chugh A et al. (2003) Catheter ablation for paroxysmal atrial fibrillation: segmental pulmonary vein ostial ablation versus left atrial ablation. Circulation 108: 2355–2360

    Article  PubMed  Google Scholar 

  82. Cappato R, Calkins H, Cgen SA et al. (2005) Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circulation 111: 1100–1105

    Article  PubMed  Google Scholar 

  83. Hsu LF, Jais P, Sanders P et al. (2004) Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med 351: 2373–2383

    Article  PubMed  CAS  Google Scholar 

  84. Wood MA, Brown-Mahoney C, Kay GN et al. (2000) Clinical outcomes after ablation and pacing therapy for atrial fibrillation: a meta-analysis. Circulation 101: 1138–1144

    PubMed  CAS  Google Scholar 

  85. Pappone C, Oral H, Santinelli V et al. (2004) Atrio-esophageal fistula as a complication of percutaneous transcatheter ablation of atrial fibrillation. Circulation 109: 2724–2726

    Article  PubMed  Google Scholar 

  86. Scanavacca MI, D’avila A, Parga J et al. (2004) Left atrial-esophageal fistula following radiofrequency catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol 15: 960–962

    PubMed  Google Scholar 

  87. Andersen HR, Nielsen JC, Thomsen PE et al. (1997) Long-term follow-up of patients from a randomized trial of atrial versus ventricular pacing for sick-sinus syndrome. Lancet 350: 1210–1216

    Article  PubMed  CAS  Google Scholar 

  88. Conolly SJ, Kerr CR, Gent M et al. (2000) Effects of physiologic pacing versus ventricular pacing on the risk of stroke and death due to cardiovascular causes. Canadian Trial of Physiologic Pacing Investigators. N Engl J Med 342: 1385–1391

    Article  Google Scholar 

  89. Lamas GA, Orav EJ, Stambler BS et al. (1998) Quality of life and clinical outcomes in elderly patients treated with ventricular pacing as compared with dual-chamber pacing. Pacemaker Selection in Elderly Investigators. N Engl J Med 338: 1097–1104

    Article  PubMed  CAS  Google Scholar 

  90. Lamas GA, Lee KL, Sweeney MO et al. (2002) Ventricular pacing or dual-chamber pacing for sinus-node dysfunction. N Engl J Med 346: 1854–1862

    Article  PubMed  Google Scholar 

  91. Knight BP, Gersh BJ, Carlson MD et al. (2005) Role of permanent pacing to prevent atrial fibrillation: science advisory from the American Heart Association Council on Clinical Cardiology (Subcommittee on Electrocardiography and Arrhythmias) and the Quality of Care and Outcomes Research Interdisciplinary Working Group, in collaboration with the Heart Rhythm Society. Circulation 111: 240–243

    Article  PubMed  Google Scholar 

  92. Lewalter T, Yang A, Pfeiffer D et al. (2006) Individualized selection of pacing algorithms for the prevention of recurrent atrial fibrillation: results from the VIP registry. PACE 29: 124–134

    PubMed  Google Scholar 

  93. Levy S, Ricard P, Lau CP et al. (1997) Multicenter low energy transvenous atrial defibrillation (XAD) trial results in different subsets of atrial fibrillation. J Am Coll Cardiol 29: 750–755

    Article  PubMed  CAS  Google Scholar 

  94. Blanc JJ, De Roy L, Mansourati J et al. (2004) Atrial pacing for prevention of atrial fibrillation: assessment of simultaneously implemented algorithms. Europace 6: 371–379

    Article  PubMed  Google Scholar 

  95. Friedman PA, Ip JH, Jazayeri M et al. (2004) The impact of atrial prevention and termination therapies on atrial tachyarrhythmia burden in patients receiving a dual-chamber defibrillator for ventricular arrhythmias. J Interv Card Electrophysiol 10: 103–110

    Article  PubMed  Google Scholar 

  96. Pedersen OD, Bagger H, Kober L et al. (1999) Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 100: 376–380

    PubMed  CAS  Google Scholar 

  97. Alsheikh-Ali AA, Wang PJ, Rand W et al. (2004) Enalapril treatment and hospitalization with atrial tachyarrhythmias in patients with left ventricular dysfunction. Am Heart J 147: 1061–1065

    Article  PubMed  CAS  Google Scholar 

  98. Wachtell K, Lehto M, Gerdts E et al. (2005) Angiotensin II receptor blockade reduces new-onset atrial fibrillation an d subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 45: 712–719

    Article  PubMed  CAS  Google Scholar 

  99. Maggioni AP, Latini R, Carson PE et al. (2005) Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 149: 548–557

    Article  PubMed  CAS  Google Scholar 

  100. Olsson LG, Swedberg K, Ducharme A et al. on behalf of the CHARM Investigators (2006) Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction. Results from the Candesartan in Heart failure-Assessment of reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol 47: 1997–2004

    Article  PubMed  Google Scholar 

  101. Young-Xu Y, Jabbour S, Goldberg R et al. (2003) Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol 92: 1379–1383

    Article  PubMed  CAS  Google Scholar 

  102. Siu CW, Lau CP, Tse HF (2003) Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. Am J Cardiol 92: 1343–1345

    Article  PubMed  CAS  Google Scholar 

  103. Mozaffarian D, Psaty BM, Rimm EB et al. (2004) Fish intake and risk of incident atrial fibrillation. Circulation 110: 368–373

    Article  PubMed  Google Scholar 

  104. Hsu LF, Jais P, Sanders P et al. (2004) Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med 351: 2373–2383

    Article  PubMed  CAS  Google Scholar 

  105. Kuck KH, Ernst S, Dorwarth U et al. (2007) Guidelines für catheter ablation. Clin Res Cardiol 96: 833–849

    Article  PubMed  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Authors
  1. T. Lewalter
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Tebbenjohanns
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T. Wichter
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Antz
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C. Geller
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. K.-H. Seidl
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. D. Gulba
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. F.R. Röhrig
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. S. Willems
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lewalter, T., Tebbenjohanns, J., Wichter, T. et al. Kommentar zu „ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation – executive summary“. Kardiologe 2, 181–205 (2008). https://doi.org/10.1007/s12181-008-0080-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12181-008-0080-2

Search

Navigation